A Prospective Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Small Vessel De Novo Coronary Artery Lesion in Japan.
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Boston Scientific Corporation
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 10 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.